63111-79-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Chloroimidazo[1,2-a]pyridine is used as a chemical intermediate for the synthesis of medicinal compounds. Its unique structure and properties make it a valuable component in the development of new drugs and pharmaceuticals. The exact properties such as toxicity, environmental persistence, and potential uses in manufacturing or synthesis are further areas of study, which could lead to its application in creating more effective and safer medications.
Used in Chemical Research:
5-Chloroimidazo[1,2-a]pyridine is used as a research compound in the field of organic chemistry. Its structure and properties are of interest to scientists studying the synthesis and reactions of heterocyclic compounds. 5-Chloroimidazo[1,2-a]Pyridine's potential applications in various chemical processes and its role in the development of new chemical methodologies are areas of ongoing investigation.
Used in Material Science:
5-Chloroimidazo[1,2-a]pyridine may be used as a component in the development of new materials with specific properties. Its unique structure and potential reactivity could contribute to the creation of advanced materials with applications in various industries, such as electronics, energy storage, or even in the development of new catalysts for chemical reactions.

InChI:InChI=1/C7H5ClN2/c8-6-2-1-3-7-9-4-5-10(6)7/h1-5H

Upstream product

• 107-20-0 2-chloroethanal 
• 45644-21-1 6-chloropyridin-2-amine 
• 97-97-2 chloroacetaldehyde dimethyl acetal 

Downstream Products

• 198895-50-0 5-chloro-3-formylimidazo[1,2-a]pyridine 
• 112266-60-1 5-mercaptoimidazo[1,2-a]pyridine 
• 31409-09-3 5-Methoxy-imidazo<1,2-a>pyridin 

Relevant academic research and scientific papers

BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS

Described herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R 4, Y1, Y2, n and p are as defined herein.

BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS

This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS

The invention relates to compounds of formula (I) wherein R, R0, R1, m, n and X1 to X4 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

Discovery of piperazinylimidazo[1,2-a]pyridines as novel S4 binding elements for orally active Factor Xa inhibitors

We have recently reported the discovery of orally active sulfonylalkylamide Factor Xa (FXa) inhibitors, as typified by compound 1 (FXa IC50 = 0.061 μM). Since the pyridylpiperidine moiety was not investigated in our previous study, we conducted detailed structure-activity relationship studies on this S4 binding element. This investigation led to the discovery of piperazinylimidazo[1,2-a]pyridine 2b as a novel and potent FXa inhibitor (FXa IC50 = 0.021 μM). Further modification resulted in the discovery of 2-hydroxymethylimidazo[1,2-a]pyridine 2e (FXa IC50 = 0.0090 μM), which was found to be a selective and orally bioavailable FXa inhibitor with reduced CYP3A4 inhibition.